Clinical Trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07875933) titled 'Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects' on Oct. 01.

Brief Summary: This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condition: H. Pylori Eradication Therapy

Intervention: DRUG: JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg

Orally, twice daily

DRUG: Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg

Orally, twice daily

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Onconic Therapeuti...